The global Urothelial Carcinoma Treatment Market size was valued at USD 3.2  billion in 2021, growing at a CAGR of 19.10% during the forecast period 2022-2028. Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell carcinoma is diagnosed using the blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells and other treatments such as radiotherapy or nephroureterectomy are indicated. Global urothelial carcinoma treatment market growth is driven by increase in global prevalence rate of bladder cancer. According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world and in the year 2012 – 430,000 new cases were diagnosed. The market has many large players and actively developing and launching of new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.


Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX